17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of 1 of the following hematologic malignancies:

Acute myeloid leukemia or acute lymphoblastic leukemia

Not a candidate for potentially curative therapy
WBC ≤ 10,000/mm^3 OR WBC ≤ 40,000/mm^3 that is stable for 5 days (hydroxyurea allowed)
No acute promyelocytic leukemia

Non-Hodgkin's lymphoma (NHL), including 1 of the following subtypes:

Small lymphocytic lymphoma
Marginal zone lymphoma
Lymphoplasmacytic lymphoma
Follicular lymphoma
Mantle cell lymphoma
Diffuse large B-cell lymphoma
Anaplastic large cell lymphoma
Peripheral T-cell lymphoma
Extranodal NK/T cell lymphoma (nasal and nasal type)
Enteropathy-type T-cell lymphoma
Hepatosplenic T-cell lymphoma
Angioimmunoblastic T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
Chronic lymphocytic leukemia (CLL)

Patients with NHL or CLL must meet the following criteria:

Ineligible for, or refused potentially curative stem cell transplantation
Transformed lymphoma/Richter's transformation, defined as the transformation of low-grade lymphoma, including follicular lymphoma, CLL, or small lymphocytic lymphoma to high-grade lymphoma (i.e., diffuse large cell lymphoma) allowed at time of transformation
Evidence of ≥ 50% bone marrow involvement at the time of enrollment OR tumor tissue accessible for biopsy (for patients enrolled after the maximum tolerated dose [MTD] is determined)
Absolute neutrophil count ≥ 1,000/mm^3
Platelet count ≥ 100,000/mm^3
Relapsed or refractory disease
Willing to undergo serial bone marrow biopsy (for patients enrolled after the MTD is determined)
No untreated or active CNS leukemia or lymphoma
Performance status - ECOG 0-2
At least 12 weeks
Bilirubin ≤ 1.5 mg/dL
AST and ALT ≤ 2.5 times upper limit of normal
Creatinine ≤ 2.0 mg/dL
No uncontrolled cardiac disease
No New York Heart Association class III-IV symptomatic congestive heart failure
No unstable angina pectoris
No serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation > 3 beats in a row) within the past 6 months
No other uncontrolled cardiac arrhythmia or requiring antiarrhythmic drugs
No myocardial infarction within the past year
No active ischemic heart disease within the past year
No congenital long QT syndrome
No left bundle branch block
QTc ≥ 450 msec (for men) or 470 (for women) on ECG/EKG
No history of LVEF < 50% by MUGA or echocardiogram
Resting ejection fraction ≥ 50% by MUGA or echocardiogram
No prior history of cardiac toxicity after receiving anthracycline therapy (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, or mitoxantrone hydrochloride)
No uncontrolled pulmonary disease
No symptomatic pulmonary disease requiring oxygen or medications
DLCO (i.e., oxygen diffusion capacity) ≥ 80% on pulmonary function testing
Resting and exercise oxygen saturation ≥ 90% by pulse oximetry

No ongoing pulmonary symptoms ≥ grade 2 including any of the following:

Dyspnea on or off exertion
Paroxysmal nocturnal dyspnea
Significant pulmonary disease including chronic obstructive or restrictive pulmonary disease
No prior history of pulmonary toxicity after bleomycin or carmustine
No Medicare requirement for home oxygen (e.g., Resting O_2 saturation ≥ 90% or desaturation to ≥ 90% with exertion)
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
HIV negative
No preexisting sensory or motor peripheral neuropathy ≥ grade 2
No history of allergic reaction to eggs
No ongoing or active infection
No psychiatric illness or social situation that would preclude study compliance
No other uncontrolled illness
Prior stem cell transplantation for relapsed or refractory disease allowed
At least 2 weeks since prior immunotherapy and recovered
At least 2 weeks since prior chemotherapy (excluding hydroxyurea) and recovered
No other concurrent chemotherapy
No concurrent routine corticosteroids except for treatment of other medical problems (e.g., pulmonary, rheumatologic, or adrenal disorders)
At least 2 weeks since prior radiotherapy and recovered
No prior radiotherapy that potentially included the heart in the field (e.g., mantle)
No prior history of chest radiation
No concurrent palliative radiotherapy
At least 2 weeks since prior investigational therapy
Prior bortezomib allowed
No other concurrent commercial or investigational agents or therapies for the malignancy